Trial Profile

A randomized, open-label study to evaluate the efficacy and safety of esaxerenone compared to trichlormethiazide in patients with essential hypertension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Esaxerenone (Primary) ; Trichlormethiazide
Indications Essential hypertension
Focus Therapeutic Use
Acronyms EXCITE-HT study

Most Recent Events

01 Apr 2025 Results published in the Hypertension Research
25 Feb 2025 New trial record
01 Feb 2025 A subgroup analysis of this trial evaluating home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension published in the Hypertension Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com